SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Rhea-AI Summary

SAB BIO (NASDAQ: SABS) has announced a Research and Development webinar scheduled for January 28, 2025, at 8:00 AM EST to discuss topline data from the Phase 1 clinical trial of its lead candidate, SAB-142. The therapy is being developed as a potential disease-modifying treatment for type 1 diabetes (T1D), utilizing the company's novel immunotherapy platform that develops human anti-thymocyte immunoglobulin (hIgG).

The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader Dr. Michael Haller, who serves as the division chief of Pediatric Endocrinology at the University of Florida. A live Q&A session will follow the presentations, and a replay will be available on the company's website.

Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST

MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology.

Webinar Details and Registration Information

Date: Tuesday, January 28, 2025

Time: 8:00 am ET

Register for the event here or join the conference call through the Events section of the SAB BIO Company website.

A live question and answer session will follow the formal presentations. A replay of the call will be available in the Presentation section of the SAB BIO Company website upon conclusion of the event.

About the Phase 1 Trial for SAB-142

The Phase 1 trial of SAB-142 is designed as a randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study in healthy volunteers and participants with T1D. The objectives of the study include establishing the safety, tolerability, pharmacokinetic (PK), immunogenicity and pharmacodynamic (PD) profile for SAB-142.

“I look forward to sharing topline results of our Phase 1 trial for SAB-142 alongside an internationally recognized expert in diabetes research, Dr. Michael Haller,” stated Samuel J. Reich, Chairman and CEO of SAB BIO. “SAB-142 is a therapy with the potential to transform patients’ lives through the delay or prevention of the onset of type 1 diabetes, and this event will be an opportunity to discuss clinical milestones and in-depth data results of this important trial.”

About SAB BIO

SAB BIO (SAB) is a clinical-stage biopharmaceutical company focused on developing human, multi- targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company’s lead asset, SAB-142, targets T1D with a disease-modifying therapeutic approach that aims to change the treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, the only transgenic animal with a human artificial chromosome, SAB’s DiversitAb™ drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors. For more information on SAB, visit: https://www.SAB.bio/ and follow SAB on X and LinkedIn.

Forward-Looking Statements

Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including, the impact members of SAB’s leadership team will have on the Company’s business and results of operations, the exercise of outstanding warrants for cash, our expected cash runway and the development and efficacy of our T1D program and other discovery programs.

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Media Relations:
Kaelan Hollon
Vice President of Communications
khollon@sab.bio

Investor Relations:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com

FAQ

What are the key details of SAB BIO's upcoming Phase 1 data presentation for SAB-142?

SAB BIO will present Phase 1 topline data for SAB-142 during a webinar on January 28, 2025, at 8:00 AM EST, featuring management presentations and T1D expert Dr. Michael Haller.

What is SAB-142 being developed to treat?

SAB-142 is being developed as a disease-modifying therapy for type 1 diabetes (T1D), using SAB BIO's novel immunotherapy platform that develops human anti-thymocyte immunoglobulin (hIgG).

Who is the key opinion leader presenting at SAB BIO's January 28 webinar?

Dr. Michael Haller, division chief of Pediatric Endocrinology at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology, will be the key opinion leader presenting at the webinar.

How can investors access SAB BIO's Phase 1 data presentation webinar?

Investors can register for the webinar through the provided link or join via the Events section of the SAB BIO Company website. A replay will be available in the Presentation section afterward.